Whether developing a new drug or medical device, designing and running clinical trials can be daunting. How drugs and devices are developed differ dramatically. Study design and regulatory pathways differ; requirements for study sites, end users, training, endpoints and follow up are all variables. This paper examines the key differences and how those impact clinical development with a focus on the US regulatory environment.
IN CASE YOU MISSED IT
- Tandem stock skyrockets on Q1 sales beat, increased pump shipments
- Senseonics wins integrated CGM designation from FDA, can work with insulin pumps
- Abbott wins FDA approval for dissolving drug-eluting scaffold
- Report: Abbott files trio of patent lawsuits over CGM tech in Europe
- Dexcom stock slides despite Q1 beats, sales guidance increase